Back to top

Image: Bigstock

Esperion (ESPR) Reports Q4 Preliminary Results, Stock Down

Read MoreHide Full Article

Esperion Therapeutics (ESPR - Free Report) announced preliminary sales numbers for fourth-quarter 2020. Notably, the company’s expectation for the quarter looks gloomy. Alongside, the company also provided guidance for operating expense in 2021 and announced an agreement with privately-held Serometrix for expanding its pipeline.

The company estimates its fourth-quarter net product revenues to be between $8 million and $8.5 million in the United States. Please note that the company’s two cardiovascular drugs — Nexletol (bempedoic acid monotherapy) and Nexlizet [bempedoic acid + Merck’s (MRK - Free Report) Zetia] — were approved in February 2020 in the United States. Although estimated sales reflected almost 140% sequential growth, it seems significantly lower than market expectation.

Esperion’s shares declined 11.1% on Jan 13, following the preliminary result announcement. In fact, the stock has declined 54.1% in the past year compared with the industry’s 1.8% decrease.


We note that Esperion’s FDA-approved drugs are also approved in Europe for similar indication. The company has an agreement with Daiichi Sankyo Europe for commercializing the drug in the territory. Esperion will earn royalties on any potential sales in Europe.

During the third quarter of 2020, the company’s net product revenues were $3.3 million, reflecting sequential script growth of more than 500% for both drugs on the back of high-quality and broad managed care coverage in the United States. However, product sales growth was partially hurt due to significantly fewer patient visits to primary care physicians amid the COVID-19 pandemic. The pandemic may have affected sales during the fourth quarter as well.

The company anticipates operating expenses to be in the range of approximately $320 million to $340 million in 2021. This appears almost flat to guided total operating expense range for 2020, which includes R&D expense of $135-$145 million and SG&A expense of $200-$210 million.

Meanwhile, the company in-licensed an oral PCSK9 inhibitor program from Serometrix for an upfront payment of $12.5 million. Following the approval of its now commercialized drugs, the company had no pipeline candidates. A successful development of the candidate will boost its cardiovascular portfolio of drugs. Currently, there are two FDA-approved PCSK9 inhibitor — Regeneron/Sanofi’s (SNY - Free Report) Praulent and Amgen’s (AMGN - Free Report) Repatha — which are administered subcutaneously. An oral PCSK9 inhibitor will provide patients another option with convenient administration for lowering bad cholesterol.

Esperion plans to develop Serometrix’s PCSK9 inhibitor as monotherapy as well as in combination with bempedoic acid. The company will update on potential submission for an investigation new drug application to begin clinical studies on the PCSK9 inhibitor program later this year.

Zacks Rank

Esperion currently carries a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Legal Marijuana: An Investor’s Dream

Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.

Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.

Download Marijuana Moneymakers FREE >>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Sanofi (SNY) - free report >>

Merck & Co., Inc. (MRK) - free report >>

Amgen Inc. (AMGN) - free report >>

Esperion Therapeutics, Inc. (ESPR) - free report >>

Published in